Skip to main content
Equibles
FLNA logo

FLNA · Filana Therapeutics, Inc.

Track FLNA — free

Use FLNA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.93 +0.01 (+0.65%) At close · Aug 28
Rebalance outlook locked
Market Cap
$44.88M
Shares
48.31M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.93 Open$0.93 Day$0.91–0.93 52W close$0.87–4.64 Avg vol 30d289K Short int6.3M · 13.1% float · 18.6d Short vol82% Last earningsMay 7, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Nov 4, 2027 Est · unconfirmed · in 61 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 29, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −48%
below
Price vs 50-day avg −11%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 2%
near low
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −56%
trailing
YTD return −53%
this year
Relative strength −70%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-15% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.06% of float · ▼ -2.3% MoM · 18.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
87 holders — near 3-yr low, contrarian setup
Squeeze score 66
elevated · 0–100
Fundamentals
Weak
Revenue growth +278%
Y/Y
EPS growth −29%
Y/Y
Free cash flow $-32.8M
Quant / Vol
risk profile
Very High
Volatility 90%
annualized · 1-yr
Max drawdown −81%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 29, 2026
second-half 2026
Net cash used in operations Initiated $11M – $15M
year-end 2026
Unrestricted cash $36M – $40M
Prior guidance period ended · from the 8-K filed Nov 12, 2025
Cash at year-end 2025 · year-end 2025 $92M – $96M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−48% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
2% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-15% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.06% of float · ▼ -2.3% MoM · 18.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
87 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 2% Range high $5
vs 200-day avg -48% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Net cash used in operations 8.9M Q1 2026 —
Shares outstanding 48.3M Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FLNA
Filana Therapeutics, Inc.
this stock
$44.88M -53.1% +277.6% — 13.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +2.9% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
87
% held
27.5%
Net QoQ
-1.2M sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
34
View
Short & Settlement
Short Interest Falling
Shares short
6.3M
Days to cover
18.6d
Change
-150.3K sh
View
Short Volume
Short vol %
82%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
233
Value
$305
As of
Jul 8, 2026
View
Off-Exchange
Off-exchange %
57.4%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Dec 12, 2022
View
Financials
Financials
Net income (FY)
$-91.0M
EPS diluted
$-1.88
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 29, 2026
This year
11
View
Proposed Sales
Value
$7.6K
Shares
2.0K
Filed
Dec 2, 2024
View
Earnings & Events
Earnings Calls
Last call
May 7, 2026
View

Performance

5D 20D 120D MTD YTD
FLNA -3.2% -8.0% -56.2% -8.0% -53.1%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -3.7% -11.0% -69.6% -11.0% -65.9%
Key facts CIK 1069530 CUSIP 14817C107 13F (30d) 69 filings 69 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)